Australia Fast-Tracks Over 40 COVID-19 Tests; Concern Emerges Over Sensitivity Claims
Executive Summary
The country's Therapeutic Goods Administration has explained how sponsors can apply for expedited approval of tests for COVID-19 and what special conditions apply. Meanwhile, post-market reviews of two approved serology-based COVID-19 point-of-care tests suggest they are not as sensitive as their manufacturers had claimed.
You may also be interested in...
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.
Quotable: Top Experts On Policy Hot Topics
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.